Minocycline safety and tolerability in Huntington disease

Neurology. 2004 Aug 10;63(3):547-9. doi: 10.1212/01.wnl.0000133403.30559.ff.

Abstract

Minocycline is an antibiotic with anti-inflammatory and antiapoptotic properties that prolongs survival in a transgenic Huntington disease (HD) mouse model. In a double-blind, randomized, placebo-controlled study of minocycline in 60 HD patients, the authors determined that over 8 weeks, minocycline at 100 and 200 mg/day was well tolerated and safe in HD patients. Tolerability and adverse event frequency were similar between treatment and placebo groups.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Apoptosis / drug effects
  • Caspase 3
  • Caspase Inhibitors
  • Cysteine Proteinase Inhibitors / administration & dosage
  • Cysteine Proteinase Inhibitors / adverse effects
  • Cysteine Proteinase Inhibitors / therapeutic use*
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Gastrointestinal Diseases / chemically induced
  • Humans
  • Huntington Disease / drug therapy*
  • Male
  • Middle Aged
  • Minocycline / administration & dosage
  • Minocycline / adverse effects
  • Minocycline / therapeutic use*
  • Patient Dropouts
  • Treatment Failure
  • Treatment Outcome

Substances

  • Caspase Inhibitors
  • Cysteine Proteinase Inhibitors
  • CASP3 protein, human
  • Casp3 protein, mouse
  • Caspase 3
  • Minocycline